GlassScriptPhysician profile
Yevgeny Kats
NPI 1063512515
$5,086.16
in general payments reported to CMS, 2019-2025
29 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $314 · 2021: $867 · 2022: $2,321 · 2023: $264 · 2024: $617 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,478.08 | 2022 | |
| Zimmer Biomet Holdings, INC. | $648.61 | 2020-2021 | |
| Smith+Nephew, INC. | $574.89 | 2020-2025 | Oasis, Grafix, Stravix |
| Fortis Surgical, LLC | $253.00 | 2022 | |
| Kerecis Limited | $247.16 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Melinta Therapeutics, LLC | $238.56 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $143.65 | 2022-2025 | Nuzyra |
| Depuy Synthes Sales INC. | $125.78 | 2023-2025 | Na, Va-Lcp, Minibunion |
| Lifenet Health | $125.13 | 2024 | Theragenesis Wound Matrix |
| Ibsa Pharma INC. | $125.00 | 2024 | Licart |
| Horizon Therapeutics Plc | $122.99 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $117.69 | 2025 | Purified Cortrophin Gel |
| Acumed LLC | $116.89 | 2024-2025 | Osteomed, Acumed, Acumed |
| Integra Lifesciences Corporation | $110.51 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $100.12 | 2022-2023 | Seglentis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $84.23 | 2019-2023 | Puraply |
| Bioventus LLC | $72.50 | 2022 | |
| Ortho Solutions INC | $62.31 | 2024 | |
| Boston Scientific Corporation | $54.30 | 2022 | |
| Medtronic, INC. | $45.70 | 2023 | Intellis Adaptivestim, Closurefast |
| Heron Therapeutics, INC. | $40.67 | 2021-2022 | |
| Biocomposites INC | $37.33 | 2019 | |
| Stryker Corporation | $32.76 | 2025 | Prostep Mica |
| Hartmann USA, INC. | $25.63 | 2021 | |
| Rikco International, LLC | $24.58 | 2019 | |
| Nevro Corp. | $22.15 | 2024 | Senza |
| Triad Life Sciences INC. | $22.12 | 2022 | |
| Osteomed LLC | $21.56 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yevgeny Kats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.